BCR-ABL-IN-7

• UNSPSC Description:

  BCR-ABL-IN-7 (compound 4) is a WT and T315I mutant ABL kinases inhibitor. BCR-ABL-IN-7 effectively inhibits activities of WT and T315I mutant ABL kinases. BCR-ABL-IN-7 can be used for the research of chronic myeloid leukemia (CML) research[1].

• Target Antigen:

  Bcr-Abl

• Type:

  Reference compound

• Related Pathways:

  Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/bcr-abl-in-7.html

• Purity:

  98.0

• Solubility:

  DMSO : 2 mg/mL (ultrasonic;warming;heat to 60°C)

• Smiles:

  O=C(C1=C(NC(C2=NOC(C3=CC=C(F)C=C3)=C2)=O)SC4=C1CCCC4)N

• Molecular Weight:

  385.41

• References & Citations:

  [1]Cao R, et al. Discovery of 2-Acylaminothiophene-3-Carboxamides as Multitarget Inhibitors for BCR-ABL Kinase and Microtubules. J Chem Inf Model. 2015 Nov 23;55(11):2435-42.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, protect from light)

• Clinical Information:

  No Development Reported

• CAS Number:

  688050-42-2